Immuneering Corporation — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021; comparisons are with FY2020. This is an annual report, not a standalone fourth-quarter report. Immuneering is a clinical-stage-preparation biopharmaceutical company focused on oncology and neuroscience drug candidates and translational bioinformatics. It had no approved products and had not begun clinical trials by year-end.
Financial performance and liquidity
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | $2.08 million | $2.31 million |
| Gross profit / gross margin | $0.93 million / 44.6% | $1.03 million / 44.6% |
| Research and development expense | $26.54 million | $15.00 million |
| General and administrative expense | $8.27 million | $3.11 million |
| Operating loss | $33.89 million | $17.08 million |
| Net loss | $33.54 million | $17.04 million |
| Net loss per share, basic and diluted | $2.46 | $3.44 |
| Cash used in operating activities | $30.85 million | $14.62 million |
- Revenue came from computational biology services, not product sales. Revenue declined 10%, and management expected to wind down external services revenue by the end of 2022.
- R&D expense rose 76.9%, primarily reflecting increased outside research services and employee costs. G&A expense rose 166%, including higher employee costs, professional fees, stock compensation, and other expenses.
- At December 31, 2021, cash and cash equivalents were $74.9 million and marketable securities were $75.3 million, totaling approximately $150.2 million. Management estimated this would fund operations and capital needs into the third quarter of 2024, subject to assumptions and potential faster-than-expected cash use.
- Current assets were $152.3 million and current liabilities $5.6 million. The filing reports no material off-balance-sheet arrangements and no conventional borrowings in the presented balance sheet. Lease liabilities totaled $5.36 million, including $0.27 million current and $5.09 million long-term.
- Operating cash use increased year over year. Investing activities used $75.6 million, mainly for purchases of marketable securities; financing provided $144.3 million, including IPO proceeds and Series B preferred-stock proceeds.
Material changes and unusual items
- Immuneering completed its IPO in August 2021 and reported approximately $120.3 million of net proceeds before $2.1 million of offering costs. Preferred shares converted into Class A common stock at the IPO.
- In December 2021, the company acquired BioArkive, a preclinical research services and biosample-storage business, for stock. The preliminary fair value of consideration was $7.875 million; the acquisition added $6.7 million of goodwill and $0.44 million of technology intangible assets. BioArkive was being integrated to support internal oncology research.
- The filing reports a $0.31 million income-tax benefit associated with the BioArkive business combination; the company continued to maintain a full valuation allowance on net deferred tax assets.
- Net loss per share improved despite a larger net loss, principally alongside a higher weighted-average share count following financing and the IPO; FY2021 weighted-average shares were 13.6 million versus 5.0 million in FY2020.
Outlook, management commentary, and key risks
- IMM-1-104, the lead dual-MEK inhibitor candidate for advanced solid tumors with RAS mutations, remained in IND-enabling studies. Management planned an FDA IND submission in Q3 2022 and a first Phase 1 patient in Q4 2022, subject to IND acceptance. The filing says supply-chain constraints delayed the planned submission from Q1 2022.
- IMM-6-415 was in IND-enabling studies, with an IND planned for 2023; management anticipated at least one additional oncology IND in 2024. Other oncology and two neuroscience programs remained at discovery stages.
- Management expected continued operating losses and increasing R&D, G&A, and capital needs. The company may need additional financing beyond its estimated runway; financing might dilute shareholders or require unfavorable terms.
- Key risks include the absence of human clinical data, uncertainty in translating preclinical results, regulatory and trial delays, adverse effects, patient enrollment, reliance on third-party manufacturers and research organizations, supply-chain disruption and COVID-19 impacts, competition, and limited patent protection. The company also depends on its DCT and Fluency platform and on retaining specialized staff.
- Preclinical findings cited for IMM-1-104 and IMM-6-415 are not clinical evidence; efficacy and tolerability claims remain unverified in patients. No material legal proceedings were reported.
Most important facts for investors to verify
- Whether the IMM-1-104 IND and first-patient timelines were achieved, and whether supply constraints or regulatory feedback caused further delays.
- Cash, marketable securities, quarterly operating cash use, and whether the stated Q3 2024 runway remains supportable as clinical spending increases.
- Clinical safety, tolerability, and efficacy data for lead candidates, when available, rather than relying on preclinical comparisons.
- Progress and costs of integrating BioArkive, the final purchase accounting, and the related-party context: its founder and board chair was Immuneering’s Chief Scientific Officer, and BioArkive had provided services to Immuneering before acquisition.
- The pace of the planned services-business wind-down, dilution from equity compensation or future financing, and the strength and scope of patent protection for product candidates and platform technology.